Difference between revisions of "Part:BBa K1228006"

 
Line 1: Line 1:
−
 
 
__NOTOC__
 
__NOTOC__
 
<partinfo>BBa_K1228006 short</partinfo>
 
<partinfo>BBa_K1228006 short</partinfo>
Line 18: Line 17:
 
<partinfo>BBa_K1228006 parameters</partinfo>
 
<partinfo>BBa_K1228006 parameters</partinfo>
 
<!-- -->
 
<!-- -->
 +
 +
== Reference ==
 +
BellamyW，TakaseM，Yamauchi K，et al. Identification of the bactericidal domainof lactoferrin［J］． Biochimicaet BiophysicaActa，1992，1121( 1/2) : 130－136.
 +
EliassenLT，Berge G，SveinbjornssonB，et al. Evidenceforadirect antitumormechanismof actionof Bovine lactoferricin［J］． Anticancer Research，2002，22( 5) :2703－2710
 +
Wakabayashi H，TakaseM，TomitaM. Lactoferricinderivedfrommilkproteinlactoferrin［J］． Current Pharmaceutical Design，2003，9( 16) : 1277－1287.

Revision as of 07:35, 27 September 2013

25aa with T1 terminator and Constitutive promoter veg

Lf (loctoferrin) is located in many key body fluids , e.g., milk, tears, saliva and other secretions, and in white blood cells ,it has become clear that it is an important part of mammalian defence mechanisms, with a wide range of protective functions.25 amino acid residues is from Lf but has a strong bactericidal, bacteriostatic ability, and the antimicrobial activity than natural LF.We add T1 terminator and Constitutive promoter veg on the 25aa to make it can work regularly.


Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Reference

BellamyW，TakaseM，Yamauchi K，et al. Identification of the bactericidal domainof lactoferrin［J］． Biochimicaet BiophysicaActa，1992，1121( 1/2) : 130－136. EliassenLT，Berge G，SveinbjornssonB，et al. Evidenceforadirect antitumormechanismof actionof Bovine lactoferricin［J］． Anticancer Research，2002，22( 5) :2703－2710 Wakabayashi H，TakaseM，TomitaM. Lactoferricinderivedfrommilkproteinlactoferrin［J］． Current Pharmaceutical Design，2003，9( 16) : 1277－1287.